ATPase Inhibitory factor 1 (IF1) is an endogenous regulator of mitochondrial ATP synthase, which is involved in cellular metabolism. Although great progress has been made, biological roles of IF1 and molecular mechanisms of its action are still to be elucidated. Here, we show that IF1 is present in pancreatic b-cells, bound to the ATP synthase also under normal physiological conditions. IF1 silencing in model pancreatic b-cells (INS-1E) increases insulin secretion over a range of glucose concentrations. The left-shifted dose-response curve reveals excessive insulin secretion even under low glucose, corresponding to fasting conditions. A parallel increase in cellular respiration and ATP levels is observed. To conclude, our results indicate that IF1 is a negative regulator of insulin secretion involved in pancreatic b-cell glucose sensing.
Impaired insulin secretion by pancreatic b-cells is an important hallmark of type 2 diabetes [1] . Thus, understanding the mechanisms involved in glucose-stimulated insulin secretion (GSIS) is of major significance. ATP is an important downstream signal of nutrient metabolism, which stimulates insulin release by pancreatic b-cells. The ATP/ADP ratio plays a crucial role in upregulation of GSIS via controlling closure of ATP-sensitive potassium channels (K ATP ), subsequent plasma membrane depolarization, and activation of voltage-gated L-type Ca 2+ channels [2] [3] [4] . The resulting increase in submembrane Ca 2+ concentration stimulates exocytosis of insulin granules [5] . Besides regulation of potassium channels, ATP is supposed to stimulate the augmentation pathways of GSIS, for example, via regulation of PKA or AMPK signaling [6] [7] [8] [9] .
The vast majority of ATP in pancreatic b-cells is synthesized by mitochondrial ATP synthase and, consequently, its endogenous regulators are likely to have an impact on GSIS and might be part of the GSIS regulatory mechanism. One of the most studied interaction partners of the ATP synthase is the ATPase Inhibitory Factor 1 (IF1, ATPIF1). IF1 is a small (12 kDa) highly conserved, nucleus-encoded protein which was identified in 1963 [10, 11] . Despite the importance of IF1 for cellular bioenergetics, there is no consensus about the mechanism by which IF1 regulates the ATP synthase. Previous studies have established that IF1 binds and inhibits ATP synthase upon a large decrease in the inner-membrane potential, DΨ m , when the ATP synthase reverses and hydrolyzes ATP [11, 12] . Thus, IF1 prevents total ATP depletion and consequent cell death during hypoxia or starvation, which is essential under pathological conditions like cardiac ischemia [13] [14] [15] [16] . Consistently, biochemical studies of IF1 interaction with ATP synthase showed that the interaction is favored Abbreviation BSA, bovine serum albumin; FAF, fatty acid free; FCCP, trifluoromethoxy carbonylcyanide phenylhydrazone; GSIS, glucose-stimulated insulin secretion; IF1, Inhibitory Factor 1; IKMC, International Knockout Mouse Consortium; KRH, Krebs-Ringer-Hepes; OSR, oligomycin-sensitive respiration; PI, pancreatic islets; PKA, protein kinase A; SIM, Structured Illumination Microscopy.
by low matrix pH [17] [18] [19] [20] . Below pH 6.7, IF1 forms dimers with the monomers associated via an antiparallel a-helical coiled coil composed of residues 74-106, leaving each N-terminal inhibitory region unmasked and available for interaction with a-/binterphase of the ATP synthase. However, at higher pH, the inhibitor forms tetramers by coiled coil interactions involving the N-terminus and thus prevents the interaction with ATP synthase [20] [21] [22] . Consequently, under normal physiological conditions when there is a sufficient supply of fuel and oxygen, and ATP synthase synthetizes ATP, IF1 is not expected to regulate the enzyme [21] [22] [23] .
Nonetheless, recent studies reported that IF1 can regulate also the forward synthesis mode of the ATP synthase [24] [25] [26] . IF1 has been proposed to inhibit the ATP synthase, and act as a switch between the OXPHOS metabolism, i.e. with oxidative phosphorylation as the dominant source of ATP, and Warburg phenotype, i.e. when a majority of ATP is gained via glycolysis [27] [28] [29] . Consistently, high overexpression of IF1 has been reported in tumors or stem cells, where the oxidative phosphorylation is reduced and the Warburg effect is prevalent [24, [30] [31] [32] [33] . The inhibitory effect of IF1 on H + translocation by the ATP synthase is regulated by protein kinase A-(PKA-) mediated phosphorylation of IF1 at serine-39 (S39) [34] . According to the authors, IF1 phosphorylated at this position represents the inactive form of the protein and only the dephosphorylated protein has the ability to inhibit both the synthetic and hydrolytic activity of the ATP synthase. In this view, IF1 can function as one of the executive mechanisms enabling the PKA signaling pathway to adjust cellular metabolism according to the physiological needs [34] .
Ambiguous results were reported regarding the phenotype of IF1 knockout mice. According to Nakamura et al. [35] , IF1 KO mice breed and grow normally; and no significant difference was detected in their ATP synthase activity. On the other hand, IF1 KO mice (EPD0158_4_B04), generated by the International Knockout Mouse Consortium (IKMC), have decreased body weight and decreased total body fat amount, indicating alterations in metabolic regulations [36] . Furthermore, studies using transgenic mice overexpressing active form of IF1 in neurons or hepatocytes had decreased ATP synthase activity in isolated mitochondria and downregulated tissue ATP levels, supporting the role of IF1 as an inhibitor of ATP synthesis [28, 29] .
Interestingly, increased ratio of IF1 to b subunit of ATP synthase was recently reported in muscle biopsies of obese and type 2 diabetes patients. [37] .
In this study, using rat clonal pancreatic b-cells (INS-1E) we report that IF1 silencing leads to a pronounced increase in insulin release and shifts the insulin/glucose dose-response curve to the left, making it hyperbolic with sharp increase from nearly zero glucose, in contrast to S-shape responses in nontransgenic control INS-1E cells.
Materials and methods

Chemicals
All chemicals were purchased from Sigma-Aldrich unless otherwise stated.
Cell culture
Rat insulinoma INS-1E cells were cultured in RPMI 1640 medium containing 11 mM glucose and supplemented with 2 mM L-glutamine, 10 
Isolation of pancreatic islets
All animal experiments complied with the ARRIVE guidelines and were carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986, and associated guidelines, EU Directive 2010/63/EU for animal experiments. Three months old Wistar rats were used in the experiment. All surgery was performed under general anesthesia (dexmedetomidine 0.25-0.5 mg per kg body plus ketamine 50 mg per kg body weight). Rat pancreatic islets (PI) were isolated following intraductal collagenase injection (1 mgÁmL
À1
; Sevapharma, Czech Republic) and Ficoll discontinuous gradient purification according to a standard protocol [38] . After isolation, PI were incubated with accutase to obtain primary pancreatic b-cells.
ATP assays
Before the experiment, siRNA-transfected cells were preincubated for 2 h in KRH buffer with 0.1% FAF BSA and indicated glucose concentrations. ATP quantification was performed using ATP Assay bioluminescence kit HSII (Roche, Basel, Switzerland) as described by the manufacturer. Briefly, cells were mixed with boiling lysis buffer (100 mM Tris, 4 mM EDTA, pH 7.75) and further boiled for 2 min. Samples were centrifuged at 10 000 g for 1 min. Diluted supernatants were mixed with luciferase reagent and a Synergy HT luminometer was used to read the bioluminescence. To confirm that the assay procedure does not interfere with the ATP concentration determination, internal ATP standards were added to the samples during the initial experiments.
Insulin assays
Cells were seeded at 0.15 9 10 6 cells/well in poly-L-lysinecoated 24-well plates 1 day before the transfection and 4 days before the experiment. Cells were extensively washed for 10 min and incubated for 1 h in KRH buffer with 0.1% FAF BSA and indicated glucose concentration. Insulin released during this period was assayed using Rat Insulin High Sensitivity ELISA kit (BioVendor, Brno, Czech Republic) in KRH buffer with 0.1% FAF BSA.
High-resolution respirometry
Cellular respiration of INS-1E was determined using an Oxygraph-2k (Oroboros, Innsbruck, Austria). Cells were trypsinized, counted by a Countess Automated Counter (Invitrogen), and adjusted to 1 9 10 6 cellsÁmL À1 . Cellular O 2 consumption was measured in the KRH buffer with 0.1% FAF BSA using an Oxygraph-2k (Oroboros, Innsbruck, Austria) after calibration at 0 and 100% air saturation. To determine O 2 consumption of non-mitochondrial origin, Antimycin A was added at the end of each run and the resulting background rates were subtracted from the measured rates. Respiratory activity was titrated by trifluoromethoxy carbonylcyanide phenylhydrazone (FCCP) at each run and the maximum respiratory chain capacity has been derived from the maximum rate achieved in a titration.
Cell transfection
The transfection was done with Lipofectamine RNAiMAX reagent according to the manufacturer's instructions. Two siRNA duplexes against Rattus Norvegicus IF1:
at a 70 nM concentration. Effects of siRNA silencing were first tested by individual RNAs to ensure specificity of the silencing. Scrambled siRNA nonspecific to any Rattus Norvegicus gene (CTRL-si) was used as a control.
Western blot immunoassay
Cells were lysed in 50 mM HEPES, 135 mM NaCl, 1 mM EDTA, 1% Triton X-100, and 1 mM PMSF (pH 7.4), and the amount of protein was quantified by bicinchoninic acid assay. Proteins separated on SDS-polyacrylamide gels were transferred by a wet electroblot onto PVDF membranes, treated subsequently with the relevant primary antibody: IF1 (Abcam, Cambridge, UK), ATP synthase a-subunit (Abcam), and VDAC (Abcam), followed by the secondary (horseradish peroxidase-conjugated) antibody. ECL detection was accomplished with a Luminata Forte Western HRP Substrate (Millipore Corporation, Billerica, MA 01821). ECL light intensity was quantified by densitometry with FIJI [39] .
Structured Illumination Microscopy (SIM)
3D high-resolution fluorescence microscopy (SIM) was carried out using a DeltaVision OMX TM with the Blaze SIM Module (GE Healthcare, Seattle, WA, USA) equipped with a 60 9 1.42, PlanApo N, Oil Immersion objective. Images were acquired in structured illumination mode using a Z spacing of 125 nm, and reconstructed using Softworx software (GE Healthcare). To prepare the cells for SIM, we fixed them in 4% paraformaldehyde for 10 min, washed them twice in PBS, and incubated them for 15 min with 5% donkey serum. Anti-IF1 (Abcam) monoclonal antibodies were used at a concentration 0.5 lgÁmL À1 for 1 h with constant shaking. Coverslips were then washed 3 times in PBS and incubated for 1 h in PBS with the Alexa-Fluor-555 secondary antibody (Thermo Fisher Scientific-Life Technologies) followed by three washes in PBS. Samples were mounted in the glycerol buffer containing antifade reagent.
3D direct stochastic optical reconstruction microscopy (dSTORM)
dSTORM microscopy was performed on a Vutara superresolution microscope (Vutara Inc., Salt Lake City, UT, USA). Cells were fixed in 4% paraformaldehyde for 5 min, washed twice in PBS, and incubated for 15 min with buffered 5% bovine serum albumin (BSA). Alexa-Fluor-647-conjugated anti-IF1 (Abcam) monoclonal antibody was used at a concentration 0.5 lgÁmL À1 for 1 h with constant shaking. Coverslips were then washed 3 times in PBS. Samples were mounted in the "dSTORM buffer" (10% glucose, 169 units of glucose oxidase, 1.4 units of catalase, 10 mM NaCl, 50 mM Cysteamine, and 50 mM Tris-HCl; pH 8.0).
Blue Native gel electrophoresis 
Statistical analysis
Data are presented as means AE S.D. For statistical analysis ANOVA, using SigmaStat 3.1 (Systat Software, Chicago, IL), was carried out with subsequent pairwise multiple comparisons (Tukey's test). Statistical significance was defined as follows: *P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.00005.
Results
IF1 is present in pancreatic b-cells, localizes to mitochondria, and is organized in clusters
Presence of the IF1 protein and its association with the ATP synthase was not yet documented in pancreatic b-cells. To demonstrate that IF1 is expressed in pancreatic b-cells, we isolated pancreatic islets (PI) and subsequently primary b-cells from adult Wistar rats. We immunostained them against IF1 and insulin as a reliable marker of pancreatic b-cells. Using 3D structured illumination microscopy (SIM), IF1 was visualized in primary b-cells and the observed signal contoured the entire mitochondrial network (Fig. 1A) . Since extra-mitochondrial localization of IF1 has been reported, we further verified that IF1 localizes specifically to mitochondria. Thus, the model pancreatic b-cell line, INS-1E, was transfected with mt-roGFP plasmid and simultaneously immunostained against IF1. The existing overlays of the respective 3D SIM images (Fig. 1B) confirmed the mitochondrial localization of IF1 in INS-1E cells.
To examine submitochondrial localization of IF1 we employed 3D super-resolution direct stochastic optical reconstruction microscopy (dSTORM) and immunostained INS-1E cells with primary antibody against IF1 directly conjugated to Alexa-Fluor-647. Interestingly, we observed that IF1 molecules are not homogenously distributed within the mitochondrial tubule but instead form clusters (Fig. 1C) . We propose that this cluster organization of IF1 is due to localization of IF1 within certain microdomains, presumably matrix compartments of mitochondrial cristae, as also mitochondrial ATP synthase and other proteins of intracristal membrane have been shown to form similar clusters [40] [41] [42] [43] .
IF1 interacts with ATP synthase under standard culturing conditions in INS-1E cells and pancreatic islets
INS-1E cells are clonal noncancerous cells which are primarily oxidative due to the low lactate dehydrogenase activity [44] . INS-1E cells represent broadly used model of GSIS on a cellular level [45, 46] . Using these cells, first, we attempted to define conditions under which IF1 is bound to the ATP synthase in b-cells. As IF1 was assumed to bind to the ATP synthase preferentially when the mitochondrial matrix pH decreases below 6.7, i.e., under conditions occurring upon starvation or hypoxia, we incubated INS-1E cells with low (3 mM) or standard cultivation (11 mM) glucose for 2 h. Note, that the 11 mM glucose is already stimulating insulin release. Subsequently, we prepared cell lysates, separated them by one-dimensional BN PAGE, followed by western blotting against the ATP synthase subunit a and IF1. We found that IF1 is associated with the ATP synthase not only at low glucose levels but also at 11 mM glucose with a similar ratio ( Fig. 2A) .
To determine whether IF1 associates to the ATP synthase also in primary pancreatic b-cells, we used lysates of pancreatic islets freshly isolated from Wistar rats and analyzed them identically. Our data confirmed that IF1 is also bound to the ATP synthase in PI (Fig. 2B ).
IF1 silencing does not alter mitochondrial volume or ATP synthase oligomerization
To examine a role of IF1 in b-cell physiology and test our hypothesis that IF1 is involved in regulation of ATP levels under standard physiological conditions, we silenced IF1 in INS-1E with siRNA. A noncoding siRNA transfection was used as a control. WB blot analysis showed that in IF1-silenced cells the expression level of IF1 protein dropped down to 18% of the amount in control cells transfected with noncoding siRNA (Fig. 3A) . We further verified that the IF1 silencing does not lead to changes in mitochondrial mass or the ATP synthase amount. We performed WB with antibody against the ATP synthase subunit a and compared its amounts between the IF1-silenced cells and controls. No significant difference was found (Fig. 3B) . Also, the amount of VDAC protein normalized to the loading control did not differ in IF1-silenced cells (Fig. 3B) . As IF1 has been previously reported to enhance the ATP synthase oligomerization, we performed a 1D BN PAGE to observe whether this is the case in our experimental model. After western blot against the ATP synthase a subunit, we observed that ATP synthase dimers and higher oligomeric supercomplexes were organized in the same way in IF1-silenced cells as in the controls, and no difference was detected in the dimer/monomer ratios (Fig. 3C ).
IF1 silencing changes INS-1E cell bioenergetics
Assays of ATP levels by bioluminescence revealed a remarkable increase in ATP levels of IF1-silenced cells over a studied range of glucose concentrations (0-20 mM) (Fig. 4A) . Increasing glucose doses gradually upregulated ATP levels in both the controls and IF1-silenced cells. Maximum ATP levels were observed at 14 mM glucose in controls and at 11 mM glucose in IF1-silenced cells and a small gradual decrease was observed at higher concentrations. When the differences were analyzed between the IF1-silenced cells and the controls, we found that IF1 silencing causes a significant increase in ATP levels under all conditions. The most pronounced effect of silencing on ATP upregulation was observed at low glucose concentrations (Fig. 4B) . The data of 0-11 mM glucose were taken, where ATP levels increased in response to higher glucose dose, and the half maximum glucose concentration was estimated (Fig. 4C) . For control cells, the glucose-ATP dose-response exhibited sigmoidal character with a half maximum glucose concentration of 4.8 mM and maximum ATP levels of 3.35Á10 À9 molÁ10 6 cells À1 . In contrast, the obtained dose-response curve for IF1-silenced cells had a hyperbolic shape, half maximum glucose concentration dropped to 2 mM, and maximum ATP levels were increased by 75% to 5.89Á10 À9 molÁ10 6 cells À1 . In conclusion, our data show that the IF1 is an integral part of the glucose-sensing mechanism regulating coupling between glucose and ATP levels. We further studied respiratory dose-responses for IF1-silenced and control cells incubated for 2 h with various glucose concentrations (Fig. 4D) . With regard to control cells, a significant increase in respiration rates (state 3) was observed in IF1-silenced cells incubated with low (3 mM) and standard (11 mM) glucose, 43% and 45%, respectively, but not at 20 mM glucose, where respiration reached saturation in both cases. Nonphosphorylating respiration due to an H + leak (i.e. in the presence of oligomycin) slightly linearly increased in both IF1-silenced and control cells (Fig. 4D) . As a result, the ATP synthase relevant, i.e., oligomycin-sensitive respiration (OSR, state 3 minus state 4) significantly increased in IF1-silenced cells (Fig. 4E) . We conclude that within a range of insulinstimulating glucose, there is an increased ATP synthesis in the IF1-silenced cells. We also assessed the maximum capacity of the respiratory chain by uncoupled respiration, when FCCP was titrated in each respiratory assay (Fig. 4F) . Due to yet unrevealed regulations, also this maximum capacity of the respiratory chain increases with the increasing glucose. This occurs irrespectively of the presence of IF1, which implies existence of an additional mechanism which ensures bioenergetic sensitivity of pancreatic b-cells toward glucose. 
IF1-silencing augments insulin secretion and increases sensitivity of INS-1E cells to glucose
As the above results revealed higher ATP synthesis and a significant increase in ATP cellular levels in IF1-silenced INS-1E cells, we expected that also the insulin secretion should be upregulated. Indeed, we found that IF1 silencing caused a significant increase in insulin levels released after 1 h at all studied glucose concentrations (Fig. 5A) . Similarly as for the ATP quantifications, the glucoseinsulin dose-response curve in IF1-silenced cells has lost its typical sigmoidal shape exhibited in controls and was hyperbolic with the maximum insulin release observed between 7 and 14 mM glucose and then slowly decreasing. The four-parameter logistic curve fit of the data yielded a half maximum glucose concentration 6.1 mM for the control cells and 2.7 mM for IF1-silenced cells (Fig. 5B) . The plateau of insulin release rate increased 2.8 times. We also measured the time courses of insulin secretion up to 2 h in IF1-silenced cells incubated without glucose or with 11 mM glucose (Fig. 5C ). The obtained data confirmed the above measurements, showing upregulation of insulin secretion in IF1-silenced cells during the 2 h time course.
PKA activation has less pronounced effect on ATP levels and insulin secretion in IF1-silenced cells As reported previously, IF1 phosphorylation on Serine-39 by protein kinase A (PKA) can prevent its binding to the ATP synthase. We therefore tested whether IF1 is also involved in PKA signal transduction in pancreatic b-cells. We incubated INS-1E cells for 12 hours with 100 lM dibutyryl cAMP (dbcAMP, a cell permeable form of cAMP, activating PKA) and measured ATP levels. In control cells 54% increase was detected in ATP cellular levels, while in IF1-silenced cells no significant increase in the already elevated levels was observed (Fig. 6A ). Finally, we tested impact of dbcAMP treatment on insulin release in response to 11 mM glucose ( Fig. 6B) . We found that in control cells treated for 12 h with 100 lM dbcAMP a 71% upregulation of insulin release occurred, while in IF1-silenced cells no significant upregulation after this treatment was detected. Our data thus implicate that IF1 might be involved as an effector protein in the PKA signal transduction pathway in pancreatic b-cells mediating its stimulatory effect on insulin secretion.
Discussion
In this study, we document for the first time that the ATPase Inhibitory Factor 1 (IF1) is present in pancreatic b-cells and possesses a significant role in the regulation of ATP levels and insulin secretion. We have shown that IF1 is localized in pancreatic b-cell mitochondria, organized in clusters, and that it is bound to the ATP synthase also under normal physiological conditions. According to the previous reports, IF1 should bind to the ATP synthase mainly when the enzyme hydrolyzes ATP, i.e., under conditions when DΨ m is dissipated. Nevertheless, another work has already shown that IF1 association with the ATP synthase is not restricted only to conditions of hypoxia or starvation [47] . In our work we have demonstrated that this is also the case in insulin-secreting INS-1E cells and also in the isolated pancreatic islets.
Bioenergetics studies of IF1-silenced INS-1E cells confirmed a role for IF1 in regulation of cellular metabolism. We have observed that IF1 silencing in INS-1E cells lead to a remarkable upregulation of ATP cellular levels under all studied conditions. Also, the correlation with a consistent increase in phosphorylating respiration has been observed. Moreover, our data show that IF1 downregulates the ATP synthesis in a substrate-dependent manner, exhibiting more pronounced effect under low glucose concentration when compared to 11 mM (the closest concentration to a saturation of GSIS response on glucose) or higher glucose concentrations. In previous studies IF1 has been assigned a role in switching between oxidative phosphorylation and glycolysis [27] [28] [29] . Such metabolic reprogramming between OXPHOS and glycolysis can be, for instance, part of adaptation mechanisms during ischemic conditions. Nevertheless, due to the diminished Warburg phenotype in differentiated pancreatic b-cells a role of IF1 as a switch between OXPHOS and glycolysis is less plausible.
The major physiological function of pancreatic b-cells is insulin secretion, and we therefore investigated the impact of IF1 silencing on insulin release in INS-1E cells. Furthermore, a role of ATP in regulation of insulin secretion is widely accepted, however, still occasionally debated [48] . Consequently, models enabling regulation of ATP levels represent a good tool to study GSIS mechanism. Our data show that changes in insulin levels corresponded well to the changes in ATP levels. IF1-silenced cells had significantly increased insulin secretion over a range of studied glucose concentrations. The glucose/insulin dose-response curve was hyperbolic instead of typical sigmoidal and revealed that the cells are more sensitive to glucose with increased maximum insulin response. Our data thus indicate that IF1 is a key factor in the regulation of insulin secretion, setting the sensitivity of pancreatic b-cells to glucose within the appropriate physiological range.
Upregulation of protein kinase A (PKA) activity is considered as a promising target in T2DM therapy as it leads to augmented insulin secretion [49] . Interestingly, we observed that the stimulatory effect of PKA on GSIS is diminished in IF1-silenced cells, pointing to a possible role of IF1 in the PKA signaling pathway in pancreatic b-cells.
In conclusion, IF1 is an important part of the adequate glucose-sensing mechanism in pancreatic b-cells, regulating both ATP levels and insulin secretion. A large impact of IF1 on insulin release also makes it a potential target for T2DM drug development.
